Physician profile
Faisal Hamid
NPI 1063791572
$4,497.08
in general payments reported to CMS, 2019-2025
29 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.23 · 2020: $159 · 2021: $322 · 2022: $602 · 2023: $738 · 2024: $1,592 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353 · Education: $4.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.52 |
| Education | $4.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $859.27 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Lilly USA, LLC | $501.31 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $497.35 | 2022-2025 | |
| Abbvie INC. | $372.57 | 2021-2025 | |
| Amgen INC. | $332.51 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $329.69 | 2021-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $236.67 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $207.62 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.15 | 2023-2025 | Jardiance, Tradjenta, Glyxambi |
| Abbott Laboratories | $121.18 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $119.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $111.87 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $105.21 | 2024-2025 | Voquezna |
| Shield Therapeutics INC | $67.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $58.62 | 2022-2025 | Trelegy Ellipta, Benlysta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $50.83 | 2025 | Purified Cortrophin Gel |
| Renalytix Ai, INC. | $49.23 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Genzyme Corporation | $44.69 | 2022-2024 | |
| Novo Nordisk INC | $33.84 | 2022 | |
| Akebia Therapeutics INC | $28.83 | 2025 | Vafseo |
| Evoke Pharma, INC. | $27.14 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $24.32 | 2025 | Gvoke Hypopen |
| Jazz Pharmaceuticals INC. | $23.12 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $21.95 | 2022 | |
| Vifor Pharma, INC. | $21.55 | 2021 | |
| Ardelyx, INC. | $18.58 | 2024 | Ibsrela |
| Horizon Therapeutics Plc | $18.41 | 2022 | |
| Daiichi Sankyo INC. | $15.40 | 2021 | |
| Mallinckrodt Enterprises LLC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Hamid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.